Proactive Investors - Run By Investors For Investors

Dynavax announces layoffs, floats selloff of immuno-oncology arm

The biopharmaceutical company is cutting 82 positions, roughly 37% of its workforce
placeholder
As part of the transition, CEO Eddie Gray announced he would step down

Dynavax Technologies Corporation (NASDAQ:DVAX) shares stumbled Friday after the company announced layoffs and teased plans to sell off its immuno-oncology portfolio late Thursday.

The biopharmaceutical company is cutting 82 positions, roughly 37% of its workforce. The move, coupled with the decision to explore strategic alternatives for its immuno-oncology portfolio, is an effort to prioritize the company’s approved Hepatitis B vaccine, its first commercial product. ‘

Its stock climbed more than 8% early in the Friday session but swiftly reversed course, dropping 7.6% to $5.86.

“Following a comprehensive analysis of our assets, strengths and opportunities, we have determined we should focus our resources on our approved vaccine, HEPLISAV-B,” CEO Eddie Gray said. “As a result, the board and management have made the difficult decision to reduce our workforce. We want to express our deepest appreciation to our employees for their invaluable contributions.”

As part of the transition, Gray announced he would step down. The company named David Noack and Ryan Spencer as interim co-presidents as the company searches for a new CEO. Novack and Spencer serve as vice presidents of operations and commercial, respectively.

Dynavex is a company focused on using the body’s innate immune responses to develop vaccines. It launched HEPLISAV-B in February 2018 after receiving approval from the US Food and Drug Administration.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

View full DVAX profile View Profile

Dynavax Technologies Timeline

Related Articles

researcher
April 30 2019
We take a look at a company with a unique approach to drug development that may ultimately help big pharma replenish its pipeline
An illustration of Ozop's BLIF technique
March 30 2019
A key area of focus for the West Palm Beach, Florida, company is development of balloon lumbar interbody fusion (BLIF) technology
PT exercises
December 19 2018
The Californian company is a bet on an industry that is in need of transformation
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use